Novartis AG is paying $75m upfront to use Sangamo Therapeutics, Inc.'s zinc finger technology platform and develop genomic medicines for autism, a long-time area of interest for the Swiss major, and other neurodevelopmental disorders.
The three-year collaboration will see Novartis get exclusive rights to Sangamo's zinc finger protein transcription factors (ZFP-TFs) targeted to three...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
